MolecularMD Corporation, an ICON plc company

ICON Specialty Laboratories, formerly known as MolecularMD, is a CAP-accredited and CLIA-certified molecular diagnostic specialty laboratory. Founded in 2006 as a spin-off from Oregon Health & Science University, the company focuses on biomarker development and testing services to support precision medicine, particularly in oncology. After being acquired by ICON plc, it expanded its capabilities in molecular diagnostics and integrated with ICON's global network of laboratories. The laboratory offers a range of services, including centralized clinical testing, assay development, and comprehensive biomarker services. It specializes in oncology diagnostics, immunotherapy, and companion diagnostics, utilizing advanced technologies such as next-generation sequencing, PCR, and digital pathology. One of its notable products is the MRDx® BCR-ABL Test, designed for monitoring targeted therapies in cancers like chronic myeloid leukemia. ICON Specialty Laboratories primarily serves pharmaceutical and biotechnology clients, partnering to enhance therapy optimization and patient outcomes in precision medicine.